In a report released today, Tobias Gottschalt from Independent Research downgraded Qiagen (QGEN – Research Report) to Sell, with a price target of EUR35.00. The company’s shares closed last Friday at $49.45, close to its 52-week high of $51.07.
According to TipRanks.com, Gottschalt is ranked #5017 out of 6889 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Qiagen with a $51.16 average price target.
The company has a one-year high of $51.07 and a one-year low of $25.04. Currently, Qiagen has an average volume of 1.34M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.